RIVM writes Novel Tobacco Products paper for WHO The World Health Organization (WHO) Tobacco Free Initiative (TFI) has just published a Report of the WHO Study Group on Tobacco Product Regulation (TobReg).
New Lyme disease study in the Netherlands At the start of the “Tick Awareness Week”, the Dutch National Institute for Public Health and the Environment (RIVM) and Wageningen UR are commencing a large-scale study on the long-term effects of
Harmful substances in e-cigarettes assessed While e-cigarettes are less harmful to health than tobacco cigarettes, the vapour from an e-cigarette contains substances and chemical impurities in concentrations that could be detrimental to heal
RIVM researchers win best paper award of the journal Risk Analysis RIVM researchers Arie Havelaar and Arno Swart received the prestigious Best Paper Award 2014 of the Society for Risk Analysis.
RIVM and Olive Foundation open trading to mark the European Cervical Cancer Prevention Week January 20th, the Olive Foundation and RIVM opened AEX trading day in Amsterdam on the occasion of the 9th European Cervical Cancer Prevention Week.
The National Immunisation Programme in the Netherlands 2013 - 2014 Every year, RIVM provides an overview of surveillance and developments in the National Immunisation Programme (NIP).
Possibly more cases of gastroenteritis caused by antacids In recent years the Netherlands has witnessed an increase in the number of cases of gastroenteritis caused by the Campylobacter bacterium.
Increasing number of girls immunised against HPV In 2014 the number of girls who were immunised against the human papilloma virus (HPV) rose. This virus can cause cervical cancer later in life.
RIVM investigates dangers of e-cigarette At the request of State Secretary Martin van Rijn (VWS), RIVM is carrying out an investigation into the safety of e-cigarettes.
The National Immunisation Programme in the Netherlands: Developments in 2013 Annually RIVM provides an overview of key events and developments in the National Immunisation Programme (NIP).